Utilize este identificador para referenciar este registo: http://hdl.handle.net/10362/155151
Título: WNK1 phosphorylation sites in TBC1D1 and TBC1D4 modulate cell surface expression of GLUT1
Autor: Henriques, Andreia F.A.
Matos, Paulo
AS, Carvalho
Azkargorta, Mikel
Elortza, Felix
Matthiesen, Rune
Jordan, Peter
Palavras-chave: Glucose cotransport
GLUT1
Membrane traffic
Protein phosphorylation
TBC1D
WNK1
Biophysics
Biochemistry
Molecular Biology
SDG 3 - Good Health and Well-being
Data: 15-Jan-2020
Resumo: Glucose uptake by mammalian cells is a key mechanism to maintain cell and tissue homeostasis and relies mostly on plasma membrane-localized glucose transporter proteins (GLUTs). Two main cellular mechanisms regulate GLUT proteins in the cell: first, expression of GLUT genes is under dynamic transcriptional control and is used by cancer cells to increase glucose availability. Second, GLUT proteins are regulated by membrane traffic from storage vesicles to the plasma membrane (PM). This latter process is triggered by signaling mechanisms and well-studied in the case of insulin-responsive cells, which activate protein kinase AKT to phosphorylate TBC1D4, a RAB-GTPase activating protein involved in membrane traffic regulation. Previously, we identified protein kinase WNK1 as another kinase able to phosphorylate TBC1D4 and regulate the surface expression of the constitutive glucose transporter GLUT1. Here we describe that downregulation of WNK1 through RNA interference in HEK293 cells led to a 2-fold decrease in PM GLUT1 expression, concomitant with a 60% decrease in glucose uptake. By mass spectrometry, we identified serine (S) 704 in TBC1D4 as a WNK1-regulated phosphorylation site, and also S565 in the paralogue TBC1D1. Transfection of the respective phosphomimetic or unphosphorylatable TBC1D mutants into cells revealed that both affected the cell surface abundance of GLUT1. The results reinforce a regulatory role for WNK1 in cell metabolism and have potential impact for the understanding of cancer cell metabolism and therapeutic options in type 2 diabetes.
Descrição: This work was supported by Fundação para a Ciência e Tecnologia (FCT) [grants PTDC/SAU-MET/117236/2010 to PJ, grant UID/MULTI/ 04046/2019 to the research unit BioISI, and fellowship SFRH/BD/ 106080/2015 from the BioSYS PhD programme PD65-2012 to AFAH]. The authors acknowledge José Ferrão for regular mycoplasma testing in cultured cells and Patrícia Barros for critical reading of the manuscript. Anthony Albiston (Melbourne, Australia) and Florian Lang (University of Tubingen, Germany) kindly provided constucts pCR3.1/AS160-2myc or pIRES2-EGFP-SGK1, respectively, for this study.
Peer review: yes
URI: http://hdl.handle.net/10362/155151
DOI: https://doi.org/10.1016/j.abb.2019.108223
ISSN: 0003-9861
Aparece nas colecções:NMS: CEDOC - Artigos em revista internacional com arbitragem científica

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
1_s2.0_S0003986119306447_main.pdf1,19 MBAdobe PDFVer/Abrir


FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpace
Formato BibTex MendeleyEndnote 

Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.